Key result
TAVR using Evolut R showed similar device success and 1-year mortality compared to Sapien 3, but provided superior hemodynamic performance in patients with a small annulus.
Why the study?
Few studies have directly compared TAVR outcomes using third-generation THVs in patients with small aortic annuli.
Does Evolut R improve hemodynamics compared to Sapien 3 in Japanese patients with a small aortic annulus undergoing TAVR?
Cohort (n=576)
Yes
Does Evolut R improve hemodynamics compared to Sapien 3 in Japanese patients with a small aortic annulus undergoing TAVR?
In Japanese patients with a small aortic annulus, TAVR with Evolut R provides superior hemodynamics at 1 year compared to Sapien 3, though clinical outcomes like mortality are similar.
Answers are grounded in this paper and cite their sources.
Superior hemodynamics with Evolut R in small-annulus TAVR should not yet change practice; leaves open clinical impact and generalizability beyond this cohort.
Objectives To compare safety, efficacy, and hemodynamics of transfemoral transcatheter aortic valve replacement (TAVR) using self‐expanding and balloon‐expandable transcatheter heart valves (THVs) in patients with a small aortic annulus. Background Few studies have directly compared TAVR outcomes using third‐generation THVs, focusing on patients with small aortic annuli. Methods In a multicenter TAVR registry, we analyzed data from 576 patients with a small annulus and who underwent transfemoral TAVR using third‐generation THVs. Propensity score matching was used to adjust baseline clinical characteristics. Results The device success rate in the overall cohort was 92.0% (Evolut R: 92.1% vs. Sapien 3:92.0%, p = 0.96). One year after TAVR, patients treated with Evolut R maintained a lower mean pressure gradient (mPG) and a higher indexed effective orifice area (iEOA) in the matched cohort {mPG: 9.0 [interquartile range (IQR): 6.0–11.9] vs. 12.0 [IQR: 9.9–16.3] mmHg, p < .001; iEOA: 1.20 [IQR: 1.01–1.46] vs. 1.08 [IQR: 0.90–1.28] cm2/m2, p < .001}. However, no significant differences were reported in the incidence of severe prosthesis‐patient mismatch and aortic regurgitation at 1 year. Furthermore, both groups showed comparable outcomes with no differences in terms of all‐cause mortality (log‐lank test, p = .81). Conclusions TAVR for patients with a small annulus using third‐generation THVs was associated with high device success. Evolut R seems to be superior to Sapien 3 in hemodynamic performance for patients with a small annulus and body surface area up to 1 year after TAVR. Nevertheless, all‐cause mortality at 1 year was similar between both groups.
No takes yet. Share an insight, caveat, or question.
Hase et al. (2020) conducted a cohort in small aortic annulus (n=576). Evolut R vs. Sapien 3 was evaluated on device success rate (p=0.96). TAVR using Evolut R showed similar device success and 1-year mortality compared to Sapien 3, but provided superior hemodynamic performance in patients with a small annulus.
Synapse has enriched 10 related papers. Consider them for comparative context: